Author: PharmaSignal News Desk

Lilly Ventyx acquisition for $1.2B focuses on NLRP3 inflammasome drugs, expanding Lilly’s immune drug pipeline.

GSK Ionis hepatitis B drug advances to global regulatory filings, aiming for functional cures in chronic infections.

FDA approval decisions in early 2026 include multiple national priority vouchers and a gene therapy, impacting the pharmaceutical landscape.

Alumis TYK2 psoriasis drug shows promise with Phase 3 results, doubling shares and competing with Takeda and Johnson & Johnson.

Amgen acquires Dark Blue for up to $840M, gaining a protein-degrading drug targeting acute myeloid leukemia.

Moderna mRNA flu vaccine seeks US approval, aiming to boost growth in the coming years.

The FDA has approved an oral form of Wegovy, expanding treatment options for obesity.

The FDA has approved Myqorzo, marking Cytokinetics’ first drug clearance for obstructive hypertrophic cardiomyopathy.

The FDA has issued a partial clinical hold on the I-DXd trial for small cell lung cancer following unexpected patient deaths.

The application targets obesity treatment in the U.S. market.